<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845520</url>
  </required_header>
  <id_info>
    <org_study_id>CSP 002-00</org_study_id>
    <nct_id>NCT00845520</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)</brief_title>
  <official_title>A Prospective Multi-center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects Undergoing Cataract Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calhoun Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calhoun Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate, for the visual correction of aphakia, the
      safety and effectiveness of the Calhoun Vision Light Adjustable intraocular lens (LAL) and
      Light Delivery Device (LDD) in treating postoperative residual refractive error by providing
      a stable, targeted refractive adjustment of the LAL power and lock-in treatments with the
      LDD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2 medical device study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieved refractive correction</measure>
    <time_frame>3 to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>+1.00 D adjustment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LAL implant power requiring LAL power adjustment of +1.00 D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>-1.00 D adjustment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LAL implant power requiring LAL power adjustment of -1.00 D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No adjustment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LAL implant power requiring no (0.0 D) LAL power adjustment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Adjustable Intraocular Lens</intervention_name>
    <description>Subjects who require cataract extraction and intraocular lens implantation are implanted with the Light Adjustable intraocular lens. At 17 to 21 days, the manifest refraction is measured and the implanted LAL is treated with a targeted dose of light using the Light Delivery Device to produce a modification in the lens curvature, resulting in a predictable change in refractive power.</description>
    <arm_group_label>+1.00 D adjustment</arm_group_label>
    <arm_group_label>-1.00 D adjustment</arm_group_label>
    <arm_group_label>No adjustment</arm_group_label>
    <other_name>Light Adjsutable Lens; LAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Adjustable (LAL) intraocular lens requiring +1.00 D power adjustment</intervention_name>
    <description>Light Adjustable (LAL) intraocular lens requiring +1.00 D power adjustment with the Light Delivery Device (LDD)</description>
    <arm_group_label>+1.00 D adjustment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Adjustable (LAL) intraocular lens requiring -1.00 D power adjustment</intervention_name>
    <description>Light Adjustable (LAL) intraocular lens requiring -1.00 D power adjustment using the Light Delivery Device</description>
    <arm_group_label>-1.00 D adjustment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Adjustable (LAL) intraocular lens requiring no (0.00 D) power adjustment</intervention_name>
    <description>Light Adjustable (LAL) intraocular lens requiring no (0.00 D) power adjustment with the Light Delivery Device</description>
    <arm_group_label>No adjustment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-operative regular corneal astigmatism less than or equal to 1.00 diopters by
             keratometry.

          -  Adults between the ages of 40 and 80 inclusive.

          -  Cataract causing reduction in best spectacle-corrected visual acuity to a level of
             20/32 or worse.

          -  Best corrected visual acuity projected (by clinical estimate based upon past ocular
             history and retinal exam) to be 20/25 or better after cataract removal and IOL
             implantation.

          -  Clear intraocular media other than cataract.

          -  Potentially good vision in the fellow eye with BCVA 20/40 or better.

          -  Willing and able to comply with the schedule for power adjustment/lock-in treatments
             and the schedule for follow-up visits.

          -  Fully dilated pupil diameter of more than or equal to 7.0 mm.

        Exclusion Criteria:

          -  Zonular laxity or dehiscence.

          -  Pseudoexfoliation.

          -  Age related macular degeneration involving the presence of geographic atrophy or soft
             drusen.

          -  Retinal degenerative disorder that is expected to cause future vision loss.

          -  Diabetes with any evidence of retinopathy.

          -  Evidence of glaucomatous optic neuropathy.

          -  History of uveitis.

          -  Significant anterior segment pathology, such as rubeosis iridis, aniridia, or iris
             coloboma.

          -  Corneal pathology that is either progressive or sufficient to reduce BCVA to 20/25 or
             worse.

          -  Keratoconus or suspected of having keratoconus.

          -  Corneal dystrophy including basement membrane dystrophy.

          -  Previous corneal or intraocular surgery

          -  Systemic medication that may increase sensitivity to UV light such as tetracycline,
             doxycycline, psoralens, amiodarone, and phenothiazines.

          -  Complications during cataract surgery including posterior capsule rupture, zonular
             rupture, radial capsulorhexis tear, vitreous loss, iris trauma, corneal complications
             or any intraoperative abnormality that may affect the postoperative pupillary
             dilation, or the centration or tilt of the intraocular lens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Doyle Stulting, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altos Eye Physicians</name>
      <address>
        <city>Los Altos</city>
        <state>California</state>
        <zip>94024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maloney Vision Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 28, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 29, 2017</submitted>
    <returned>January 26, 2018</returned>
    <submitted>February 1, 2018</submitted>
    <returned>March 2, 2018</returned>
    <submitted>March 13, 2018</submitted>
    <returned>April 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

